Oral anticoagulants - A frequent challenge for the emergency management of acute ischemic stroke

Cerebrovascular Diseases

Volumn 34, Issue 5-6, 2012, Pages 411-418

  Rizos, Timolaos ^a   Horstmann, Solveig ^a   Jenetzky, Ekkehart ^b,c   Spindler, Marcia ^a   Gumbinger, Christoph ^a   Möhlenbruch, Markus ^a   Ringleb, Peter ^a   Hacke, Werner ^a   Veltkamp, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Child Center Maulbronn   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Acute ischemic stroke; Emergency room; International normalized ratio; Oral anticoagulants; Transient ischemic attack

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY MEDICINE; EMERGENCY WARD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RECANALIZATION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BRAIN ISCHEMIA; EMERGENCY MEDICAL SERVICES; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84870370064     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000343655     Document Type: Article

References (32)

1. Aguilar MI, Hart R: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no history of stroke or transient ischemic attacks. Stroke 2008; 39: 1399-1400. (Pubitemid 351440728)
2. Mi A, Hart R, La P: Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks (review). Cochrane Database Syst Rev 2007; 3:CD001927.
3. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262.
4. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ, American College of Chest Physicians: Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 110S-112S. (Pubitemid 351892962)
5. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE: Enoxaparin followed by onceweekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: A randomised, double-blind, double-dummy, non-inferiority trial. Lancet 2012; 379: 123-129.
6. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs M, Anderson D, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA: A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907. (Pubitemid 29141050)
7. Indredavik B, Rohweder G, Lydersen S: Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med 2005; 258: 133-144. (Pubitemid 41025970)
8. Newman D, Zhitomirsky I: The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department. Ann Emerg Med 2006; 48: 182-182.
9. Paciaroni M, Agnelli G, Caso V, Venti M, Alberti A, Milia P, Silvestrelli G, Biagini S: Prior use of antithrombotic agents and neurological functional outcome at discharge in patients with ischemic stroke. J Thromb Haemost 2006; 4: 1957-1961. (Pubitemid 44226774)
10. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026. (Pubitemid 37087616)
11. O'Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, Guyatt G, Gould L, Duva C, Kapral M, Silver F, Investigators of the Registry of the Canadian Stroke Network: Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: An observational study. Lancet Neurol 2006; 5: 749-754. (Pubitemid 44205511)
12. Lees K, Bluhmki E, Von Kummer R, Brott T, Toni D, Grotta J, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G: Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
13. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EFM: Guidelines for the early management of adults with ischemic stroke: A guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atheros. Stroke 2007; 38: 1655-1711. (Pubitemid 46691097)
14. Seet RCS, Zhang Y, Moore SA, Wijdicks EF, Rabinstein A: Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 2333-2335.
15. Kim YD, Lee JH, Jung YH, Choi HY, Nam CM, Yang JH, Cho HJ, Nam HS, Lee KY, Heo JH: Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use. J Neurol Sci 2010; 298: 101-105.
16. Matute M-C, Masjuan J, Egido J-A, Fuentes B, Simal P, Díaz-Otero F, Reig G, Diez-Teedor E, Gil-Nunez A, Vivancos J, Lecinana MA: Safety and outcomes following thrombolytic treatment in stroke patients who had received prior treatment with anticoagulants. Cerebrovasc Dis 2012; 33: 231-239.
17. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, Häppölä O, Lindsberg PJ, Mustanoja S, Piironen K, Pitkäniemi J, Rantanen K, Sairanen T, Salonen O, Silvennoinen H, Soinne L, Strbian D, Tiainen M, Kaste M: Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-1458.
18. Ruecker M, Matosevic B, Willeit P, Kirchmayr M, Zangerle A, Knoflach M, Willeit J, Kiechl S: Subtherapeutic warfarin therapy entails an increased bleeding risk after stroke thrombolysis. Neurology 2012; 79: 31-38.
19. Xiang Y, Liang L, Smith E, Schwamm L, Reeves MJ, Olson DM, Hernandez AF, Fonarow GC, Peterson ED: Risk of intracra -nial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasmino -gen activator. JAMA 2012; 307: 2600-2608.
20. Janjua N, Alkawi A, Georgiadis A, Suri MFK, Ibrahim MS, Kirmani JF, Qureshi AI: Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients. Neurocrit Care 2007; 7: 152-155. (Pubitemid 350242665)
21. Linfante I, Reddy AS, Andreone V, Caplan LR, Selim M, Hirsch J: Intra-arterial thrombolysis in patients treated with warfarin. Cerebrovasc Dis 2005; 19: 133-135. (Pubitemid 40278673)
22. Audebert HJ, Schenk B, Schenkel J, Heuschmann PU: Impact of prestroke oral anticoagulation on severity and outcome of ischemic and hemorrhagic stroke in patients with atrial fibrillation. Cerebrovasc Dis 2010; 29: 476-483.
23. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CDA, Giroud M, Rudd A, Ghetti A, Inzitari D, European BIOMED Study Care Group: Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe. Stroke 2003; 34: 1114-1119.
24. Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, Gutnikov SA, Edwards P, Mant D, Sackley CM, Farmer A, Sandercock PAG, Dennis MS, Bamford JM, Anslow P, Oxford Vascular Study: Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK, from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933. (Pubitemid 38759651)
25. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457-507.
26. Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, Spilker J, Holleran R, Eberle R, Hertzberg V: Measurements of acute cerebral infarction: A clinical examination scale. Stroke 1989; 20: 864-870. (Pubitemid 19188240)
27. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G, SITS-MOST investigators: Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): An observational study. Lancet 2007; 369: 275-282. (Pubitemid 46138121)
28. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604-607.
29. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Califf RM, ROCKET AF steering committee for the ROCKET-AF investigators: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
30. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell JA, Atar D, Avezum A, Bahit CM, Biaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L, ARISTOTLE committees and investigators: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992.
31. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RELY steering committee and investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
32. Rizos T, Herweh C, Jenetzky E, Lichy C, Ringleb PA, Hacke W, Veltkamp R: Point-ofcare international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants. Stroke 2009; 40: 3547-3551.